07:00 , Aug 11, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Estrogen-related receptor α (ERR-α; ESRRA; NR3B1); epidermal growth factor receptor 2 (HER2; ErbB2; neu)

Cancer INDICATION: Breast cancer Cell culture and mouse studies suggest combining ERR-α inhibition with the HER1 and HER2 inhibitor Tykerb lapatinib could help treat HER2-positive breast cancer. In a HER2-overexpressing, Tykerb-resistant human breast cancer cell line,...
07:00 , Apr 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Estrogen-related receptor α (ERR-α; ESRRA; NR3B1); phosphoinositide 3-kinase (PI3K); mammalian target of rapamycin (mTOR; FRAP; RAFT1)

Cancer INDICATION: Breast cancer Cell and mouse studies suggest combining inhibitors of ERR-α with inhibitors of PI3K or PI3K/mTOR could help treat triple-negative breast cancer (TNBC). In a human TNBC cell line, an ERR-α inhibitor tool compound...
07:00 , May 21, 2012 |  BC Week In Review  |  Company News

Casigen Pharma, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences deal

The institute granted newco Casigen an exclusive, worldwide license to small molecules for diabetes and other metabolic disorders. The preclinical products target estrogen-related receptor alpha (ERR-alpha; ESRRA; NR3B1). Details were not disclosed. Casigen...
00:50 , May 18, 2012 |  BC Extra  |  Company News

Diabetes company Casigen debuts

Newco Casigen Pharma Ltd. (Hong Kong, China) debuted on Thursday with an exclusive, worldwide license to small molecules for diabetes and other metabolic disorders from the Guangzhou Institute of Biomedicine and Health, Chinese Academy of...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Estrogen-related receptor-a (ERRa; ESRRA; NR3B1) Studies in patient samples and in cell culture suggest inhibiting...
07:00 , Nov 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Autoimmune disease IL-17C; IL-17 receptor E (IL-17RE) Mouse studies suggest antagonizing IL-17C or its receptor, IL-17RE,...
07:00 , Oct 6, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Estrogen-related receptor-a (ESRRA; ERRa; NR3B1); ESRRA-C11orf20 A study in patient samples identified a fusion transcript...
08:00 , Feb 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Estrogen-related receptor-a (ESRRA; ERRa; NR3B1) In vitro and rodent studies suggest diaryl ether-based thiazolidinediones that...